ICDs (implantable cardioverter defibrillators) and spine products behind solid Medtronic growth
This article was originally published in Clinica
Executive Summary
Medtronic has reported a 15% increase in third-quarter sales to $2.5bn, with earnings rising in line with revenues to $560m. 26% growth in sales of implantable cardioverter defibrillators (ICDs) to around $600m and a 24% increase in spinal revenues to about $450m were the key business drivers.